What is the immunopathobiologic mechanism of action for agents targeting IL-6 in RA? Are these MoAs synergistic with other MoAs? With which other agents should IL-6 targeting agents be used?

What is the immunopathobiologic mechanism of action for agents targeting IL-6 in RA? Are these MoAs synergistic with other MoAs? With which other agents should IL-6 targeting agents be used?

What is the precise immunopathobiologic mechanism of action for agents targeting IL-6 in the setting of RA? Are these MoAs synergistic with other MoAs? If so with which other agents should IL-6 targeting agents be used?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Peter Nash, MD

Peter Nash, MD

Professor of Department of Medicine
Director of Rheumatology Unit on the Sunshine Coast
University of Queensland
Queensland, Australia